Andrew P. Han

The FTC claimed that Illumina can and will disadvantage Grail's rivals, but lawyers for the companies said the merger's benefits outweigh "speculative harms."

Illumina faces potential fines in Europe for moving ahead with the deal but felt it had to act now in order to make sure it went through at all.

The company raised $60 million last week and will use the funding to develop and validate its DNA methylation-based tests and classifier algorithm.

The San Diego-based firm also said it expects European customers to get optical genome mapping-based assays for leukemia and FSHD accredited.

The clinical whole-genome sequencing and analysis firm is planning to add Oxford Nanopore long-read sequencing to all samples by the end of the year.

A graduate of the Y Combinator startup accelerator, the company combines shallow sequencing and data from a diverse population to predict treatment response.

The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.

Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.

The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.